Last reviewed · How we verify
Chikungunya
At a glance
| Generic name | Chikungunya |
|---|---|
| Sponsor | Bavarian Nordic |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. (PHASE3)
- Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
- Trial of an Inactivated Chikungunya Virus Vaccine (PHASE1)
- Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale (NA)
- An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults (PHASE3)
- Against Chikungunya Virus and Neonatal Infection (NA)
- Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. (PHASE3)
- Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chikungunya CI brief — competitive landscape report
- Chikungunya updates RSS · CI watch RSS
- Bavarian Nordic portfolio CI